Celalettin Camci

Publications (54)118.02 Total impact

• Article: Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey.

  Mesut Seker, Alper Sevinc, Ramazan Yildiz, Sener Cihan, Mehmet Ali Kaplan, Ayse Gokdurnali, Faysal Dane, Emel Yaman, Halit Karaca, Dilsen Colak, [......], Taflan Salepci, Abdurrahman Isikdogan, Mustafa Benekli, Metin Ozkan, Mahmut Gumus, Ugur Coskun, Celalettin Camci, Berna Oksuzoglu, Suleyman Buyukberber, Anatolian Society Of
  [show abstract] [hide abstract]
  ABSTRACT: Background/Aims: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. In an attempt to survey the approximate incidence, clinicopathological characteristics, and immunophenotypic features of GISTs in Turkey, we conducted a clinicopathological and immunohistochemical analysis of GISTs. Methodology: Three hundred and thirty-three patients with GIST from nine institutions in Turkey were retrospectively evaluated. Results: Between January 2001 and March 2011, a total of 333 patients with GISTs were included; of these, 204 (61.2%) were male and 129 (38.8%) were female. The median age was 55 years (range; 22-102 years). At the median follow-up of 26 months (range; 4-166 months), the 1-, 3- and 5-year OS rates of the 333 patients were 96.9%, 85.8% and 78.5%, respectively. The 5-year DFS rate was 40%. The 5-year OS rate and median OS time for the patients with R0 resection were significantly higher than for patients with metastatic diseases (79.7 vs. 75.7% and not reached vs. 115 months, respectively, p=0.04). Conclusion: Although our results should be confirmed by prospective studies, we believe that they contribute to the literature because the study included both resectable and metastatic or unresectable GIST patients and multicenter findings from Turkey.
  Hepato-gastroenterology 11/2012; 60(124). · 0.66 Impact Factor
• Article: Cyclooxygenase-2 expression is not a marker of poor survival in lung cancer.

  H Mehmet Turk, Celalettin Camci, Alper Sevinc, Suleyman Bukyukberber, Ibrahim Sari, Mustafa Adli
  [show abstract] [hide abstract]
  ABSTRACT: Cyclooxygenase-2 (COX-2) has been claimed to play role in carcinogenesis and be related to a bad prognosis in tumours. The aim of this study was to investigate the relationship between COX-2 expression and clinical and pathological parameters in early and advanced stage lung cancer patients. A total of 73 patients with lung cancer (27 adenocarcinomas, 33 squamous cell carcinomas, 4 large cell carcinomas and 9 small cell cancer) were analysed retrospectively. COX-2 expression was evaluated by immunohistochemistry in resection materials or lung biopsies. Tumor cells demonstrating more intense staining than smooth muscle and endothelial cells were recorded as COX-2 positive. We investigated the correlation between increased COX-2 expression and histological type of the tumor, the stage of the disease and survival. COX-2 expression was observed in 55% of the adenocarcinomas, 45% of the squamous cell carcinomas and 22% of the small cell carcinomas. No correlation was apparent between COX-2 expression and disease stage, histological type and the survival. The results of this study do not support COX-2 expression as an independent prognostic factor in lung cancer. However, since results of the literature are different, further studies made in larger series are needed.
  Asian Pacific journal of cancer prevention: APJCP 01/2012; 13(1):315-8. · 0.66 Impact Factor
• Article: Weekly topotecan for recurrent small cell lung cancer - a retrospective anatolian medical oncology group study.

  Mustafa Altinbas, Mehmet Emin Kalender, Basak Oven, Alper Sevinc, Halit Karaca, M Ali Kaplan, Suleyman Alici, Erkan Arpaci, Ramazan Yildiz, Dogan Uncu, Celalettin Camci, Mahmut Gumus
  [show abstract] [hide abstract]
  ABSTRACT: To evaluate efficacy and tolerability of topotecan treatment for recurrent small cell lung carcinoma. A total of 62 patients were evaluated retrospectively. Statistical analysis was performed using GraphPad Instat (version 3.05). Fifty five patients (89%) were male and 7 (11%) were female. Median age was 56.7 ± 9.3 (34-75). Forty eight of patients (80%) were extensive stage (ES) at the time of diagnosis. Fifty of the patients (80.6 Medical Oncology Clinic) were given median 5.36 cycles of cisplatin-etoposide (2-8 cycles). Time to recurrence was 15.6 ± 6.13 weeks in patients with limited stage (LS) and 6.3 ± 3.82 weeks in extensive stage (ES) (p<0.0001). Overall survival was 14.0 ± 6.08 months in ES and 17.9 ± 6.88 months in LS. The difference between two groups was statistically meaningful (p=0.0447). The overall survival of the patients was 14.8 ± 6.43 months (4.5-40 months). In terms of survival, there was no difference between males and females (p=0.1171). In 17 (27%) patients who were refractory to topotecan or in whom progression occurred other chemotherapies were used. Small cell lung cancer is chemosensitive, but recurrences occur in short time. Other chemotherapy regimens are used in progression. Topotecan is one of them. Patients who were young and in whom recurrences occur late had given better response to topotecan. Because of the retrospective nature of the study, we couldn't reach the records exactly and consequently, rate and duration of response couldn't be calculated. In recurrent SCLC topotecan is one of the treatment choices. But both hematological and non hematological side effects should be taken into consideration.
  Asian Pacific journal of cancer prevention: APJCP 01/2012; 13(6):2909-12. · 0.66 Impact Factor
• Article: Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.

  Ali Osman Kaya, Süleyman Büyükberber, Metin Ozkan, Necati Alkiş, Alper Sevinc, Nuriye Yildirim Ozdemir, Suleyman Alici, Onur Esbah, Veli Berk, Celalettin Camci, Arife Ulas, Uğur Coskun, Mustafa Benekli
  [show abstract] [hide abstract]
  ABSTRACT: To assess the safety and efficacy of a gemcitabine plus docetaxel regimen as a second line therapy for patients with advanced soft tissue sarcoma (STS) resistant to doxorubicin and ifosfamide-based therapy. Medical records of 64 patients with advanced STS who received gemcitabine plus docetaxel regimen as a second line treatment between May 2006 and June 2011 were examined. All patients had been previously treated with doxorubicin plus ifosfamide-based regimen at first line setting. Patients received gemcitabine 900 mg/m2 on days one and eight intravenously over 90 minutes, followed by docetaxel 75 mg/m2 on day eight intravenously over one hour. Cycles were repeated every 3 weeks. The male-to-female ratio was 37/27 and the median age was 44 years (range; 19-67 years). Objective responses were observed in 13 (20.3%) patients (2 CR, 11 PR) and stable disease in 21 (32.8%). Total clinical benefit (CR+PR+SD) was observed in 34 (53.1%). Median overall survival (OS) was 18 months (95% confidence interval (CI):12.1-23.9) and Median time to progression (TTP) was 4.8 months (95% CI: 3.6-6). A total of 243 cycles of chemotherapy were administered. The median number of cycle was 3 (range; 1-11). The most common grade 3-4 hematologic toxicity was neutropenia (35.9%). The most common nonhematologic toxicities consisted of nausea/vomiting (37.5%), mucositis (32.8%), peripheral neuropathy (29.7%), and fatigue (26%). There was no toxicity-related death. The combination of gemcitabine plus docetaxel is an active and tolerable regimen as a second line therapy for patients with advanced soft tissue sarcoma who have failed doxorubicin and ifosfamide-based therapy.
  Asian Pacific journal of cancer prevention: APJCP 01/2012; 13(2):463-7. · 0.66 Impact Factor
• Article: Peripheral blood guanylyl cyclase c (GCC) expressions are associated with prognostic parameters and response to therapy in colorectal cancer patients.

  Celalettin Camci, Akif Sahin, Alper Sevinc, Mehmet E Kalender, Serdar Oztuzcu, Ozlem N Sever, Esma Ozkara, Abdullah T Demiryürek
  [show abstract] [hide abstract]
  ABSTRACT: Guanylyl cyclase C (GCC) is expressed exclusively in normal intestinal mucosal cells, primary and metastatic colorectal cancers (CRC). The aim of this study was to determine the possible association between the GCC expressions in peripheral blood, prognostic parameters and response to chemotherapy in CRC patients. Fourty-nine metastatic CRC patients and 41 healthy controls with similar age and sex were included to this study. Peripheral blood GCC expressions are measured by the reverse transcriptase-polymerase chain reaction (RT-PCR) method. Interstingly, no GCC expression was measured in healthy controls but GCC expressions of the patients were detectable. Although there was a significant reduction in GCC expressions in 30 patients with regression (from 5.46 ± 4.12 to 0.06 ± 0.03, p < 0.0001), marked increase in GCC expressions was observed in 19 patients with progression following chemotherapy (from 0.43 ± 0.19 to 1.38 ± 0.52, p = 0.0174). Significant correlation was found between the GCC expressions and carbohydrate antigen 19-9 (CA19-9) levels (p = 0.0041) in 30 patients with regression before chemotherapy. Marked correlation was also detected between the GCC expressions and carcinoembryonic antigen (CEA) levels (p = 0.0072) in 19 patients with progression before chemotherapy. The results of the present study suggest that peripheral blood GCC expressions along with CEA and CA19-9 can be used to determine the early respose to chemotherapy in patients with metastatic CRC. These findings imply that higher expression of GCC in peripheral blood seems to be an indicator of good therapeutic response to chemotherapy and remission. Monitoring the peripheral blood GCC expressions may allow employing different treatment options to metastatic CRC patients.
  Tumor Biology 09/2011; 32(6):1265-70. · 1.94 Impact Factor
• Article: Relationship between hopelessness, loneliness, and perceived social support from family in Turkish patients with cancer.

  Seda Pehlivan, Ozlem Ovayolu, Nimet Ovayolu, Alper Sevinc, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: Life-threatening diseases such as cancer can create hopelessness and loneliness by altering the lifestyle of the patient and family. Perceived social support may facilitate coping with illness. The aim of this study was to investigate the relationship between hopelessness, loneliness, and perceived social support from family in Turkish patients with cancer. This study involved 188 patients with cancer. The data were collected using a questionnaire that determined the sociodemographic features, the Beck Hopelessness Scale, the UCLA Loneliness Scale, and Perceived Social Support from Family Scale. Data were evaluated with Mann-Whitney U and Kruskall-Wallis and Spearman product moment correlation coefficients. The mean scores of hopelessness (0-20), loneliness (20-80), and perceived social support from family (0-20) were 6.8 ± 0.4, 35.8 ± 0.8, and 15.2 ± 0.2, respectively. A statistically positive relationship existed between hopelessness and loneliness. A negative relationship between loneliness, hopelessness, and perceived social support from family was found (p < 0.05). Cancer patients who had family history of cancer and long disease duration had low social support from family. The hopelessness score was significantly higher in female, older, illiterate, and village-dwelling cancer patients. In cases where the perceived social support levels were determined to be high; the cancer patients were not hopeless or lonely. We found that decreased social support was associated with increased loneliness and hopelessness. The present evaluation indicates that although the levels of perceived social support of patients from their families may be sufficient to prevent loneliness or hopelessness, these parameters need to be evaluated periodically to maintain the patients' well-being.
  Supportive Care in Cancer 04/2011; 20(4):733-9. · 2.09 Impact Factor
• Source

  Available from: Davut Pehlivan

  Article: Esophagus cancer and IgA deficiency in a patient with Dubowitz syndrome: a case report.

  Ibrahim Halil Turkbeyler, Yavuz Pehlivan, Gazi Comez, Davut Pehlivan, Alper Sevinc, Mehmet Emin Kalender, Metin Karakok, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: Dubowitz syndrome was first described in 1965 by the English physician Dr. Victor Dubowitz. This genetic disorder causes growth retardation both before and after birth. It is primarily diagnosed through the distinctive facial features of affected individuals, including a small triangular-shaped face with a high forehead and wide-set, slitted eyes. The main method of diagnosis is through identification of facial phenotype. Esophageal mass biopsy revealed squamous cell carcinoma type. Both malignancy and IgA deficiency have been reported literature in patients with Dubowitz syndrome. However, Esophagus cancer has not been reported among the malignant tumors. Herein, we reported a patient with Dubowitz syndrome, IgA deficiency and Esophagus cancer.
  The Tokai journal of experimental and clinical medicine 01/2011; 36(2):29-30.
• Article: Another cause of pancytopenia in a patient receiving temozolomide.

  Yavuz Pehlivan, Alper Sevinc, Ibrahim Halil Turkbeyler, Ahmet Dirier, Mehmet Emin Kalender, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: To report pancytopenia caused by temozolomide, a second-generation alkylating agent. A 22-year-old patient presenting with seizures and confusion was seen in the emergency room. Cranial magnetic resonance imaging revealed a mass. After surgery, the patient was diagnosed with glioblastoma multiforme and was given temozolomide at 150 mg/m(2) on days 1 through 5 every 4 weeks. During the last cycle of temozolomide, grade 3 thrombocytopenia persisted. Possible causes of pancytopenia including vitamin B(12) deficiency were investigated. This case report shows that vitamin B(12) deficiency can be a potential cause of pancytopenia and it should be kept in mind for patients receiving chemotherapy.
  Medical Principles and Practice 01/2011; 20(4):377-9. · 0.89 Impact Factor
• Article: Irinotecan as a second-line monotherapy for small cell lung cancer.

  Alper Sevinc, Mehmet Emin Kalender, Mustafa Altinbas, Metin Ozkan, Mustafa Dikilitas, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: The present study was designed to investigate the efficacy of irinotecan monotherapy as a second-line treatment for small cell lung cancers (SCLCs). Irinotecan monotherapy was administered to 46 SCLC patients who were previously undergone cisplatin based chemotherapy protocols. Response to treatment, time to progression (TTP), overall survival rates and adverse events associated with irinotecan monotherapy (300mg/m2; total 153 cycles; mean 3.78 ∓ 1.98) were determined, retrospectively. Limited stage disease was diagnosed in 19.6% of patients (n=9) while 80.4% (n=37) were diagnosed with extensive stage cancer preceeding the irinotecan monotherapy. None of the patients had complete response to irinotecan. Partial response and stable disease were achieved among 17.5% of patients. Mean time to tumor progression (TTP) was determined to be 11.3±5.94 weeks while overall survival was 13.3±6.83 months. Considering adverse events, grade 3 and 4 toxicity was encountered in 8.9% and 4.5% of patients, respectively. Irinotecan monotherapy in brain metastasized tumors was found to be associated with significantly higher survival times compared with tumors lacking brain metastasis (15.0±5.95 vs 10.7±4.82 months; p< 0.05). Irinotecan as a monotherapy in the second-line treatment of SCLC seems to have an acceptable level of toxicity and significant palliative effects. The prominent survival step-up effect particularly in brain metastasis patients appears worthy of note.
  Asian Pacific journal of cancer prevention: APJCP 01/2011; 12(4):1055-9. · 0.66 Impact Factor
• Article: Lack of association between the Thr431Asn and Arg83Lys polymorphisms of the ROCK2 gene and diabetic retinopathy.

  Abdullah T Demiryurek, Ibrahim Erbagci, Serdar Oztuzcu, Belgin Alasehirli, Esma Ozkara, Mehmet Seker, Ayhan Sönmez, Muge Ozsan, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: To analyze the genotype distributions and allele frequencies for ROCK2 Thr431Asn and Arg83Lys polymorphisms among the diabetic retinopathy patients in a Turkish population. In this case-control study, 335 patients with diabetes mellitus were recruited and divided into three groups according to non-proliferative (n = 127), proliferative (n = 85) diabetic retinopathy, and no retinopathy (n = 123, served as a diabetic control group). Genomic DNA from the patients, and the nondiabetic healthy control cases (n = 132) was analyzed by real-time PCR using a Light-Cycler. Neither genotype distributions nor the allele frequencies for the Thr431Asn or Arg83Lys polymorphisms showed a significant difference between the groups. The haplotypes were also not significantly associated with diabetic retinopathy. These results suggest that there were no evidence for an association of ROCK2 gene Thr431Asn and Arg83Lys polymorphisms with diabetes or diabetic retinopathy in the Turkish population.
  Current eye research 10/2010; 35(12):1128-34. · 1.51 Impact Factor
• Article: Leech therapy for symptomatic relief of cancer pain.

  Mehmet Emin Kalender, Gazi Comez, Alper Sevinc, Ahmet Dirier, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: Most patients with advanced stage cancer report moderate to severe pain. The leech (Hirudo medicinalis) is commonly used in traditional medicine for relief of localized pain. We report a case of severe pain related to advanced stage cancer successfully treated by self-applied leeches. A 62-year-old male patient with synchronous renal cell carcinoma and leiomyosarcoma was admitted with severe pain in the lumbar region. The pain was refractory to radiotherapy, and systemic and epidural analgesic infusion. Two months the patient came to the clinic in good condition free of pain. The patient reported outpatient self-treatment with seven leeches to the lumbar region in the interim that resulted in complete healing of pain. This is the first report indicating possible activity of leeches in cancer pain.
  Pain Medicine 03/2010; 11(3):443-5. · 2.35 Impact Factor
• Article: Association between the Thr431Asn polymorphism of the ROCK2 gene and risk of developing metastases of breast cancer.

  Mehmet E Kalender, Seniz Demiryürek, Serdar Oztuzcu, Ayse Kizilyer, Abdullah T Demiryürek, Alper Sevinc, Mustafa Dikilitas, Ramazan Yildiz, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: The objective of this study was to analyze the genotype distributions and allele frequencies for ROCK2 Thr431Asn and Arg83Lys polymorphisms among breast cancer patients. In this case-control study, 223 patients with breast cancer were recruited and divided into two groups according to metastases (n = 128) and without metastases (n = 95). Genomic DNA from the patients and the control cases (n = 150) was analyzed by real-time PCR using a Light-Cycler. Neither genotype distributions nor the allele frequencies for the Arg83Lys polymorphism showed a significant difference between the groups. Although no marked changes were observed with nonmetastatic group, a statistically significant association was found between the control and metastatic group for the Thr431Asn polymorphism. Although homozygous carriers of the Thr431Thr genotype were more frequent, heterozygous carriers of the Thr431Asn genotype were less frequent among the metastatic patients than among controls. There was also an increase in Thr431 allele (60.5% in patients vs. 51.7% in controls) and decrease in Asn431 allele frequencies (48.3% in control vs. 39.5% in metastatic patients) in metastatic groups (p = 0.036). Our results demonstrate that Thr431Asn polymorphism of the ROCK2 gene could be a risk factor for the metastases of the breast cancer, and may help in predicting the prognosis.
  Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 01/2010; 18(11-12):583-91. · 1.30 Impact Factor
• Source

  Available from: PubMed Central

  Article: An unusual case of aplastic anemia caused by temozolomide.

  Gazi Comez, Alper Sevinc, Ozlem Nuray Sever, Taner Babacan, Ibrahim Sarı, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: Radiotherapy and concomitant/adjuvant therapy with temozolomide are a common treatment regimen for children and adults with high-grade glioma. Although temozolomide is generally safe, it can rarely cause life-threatening complications. Here we report a case of a 31-year-old female patient who underwent surgical resection followed by radiotherapy plus concomitant temozolomide. She developed pancytopenia after adjuvant treatment with temozolomide. A bone marrow aspiration and biopsy showed hypocellularity with very few erythroid and myeloid cells, consistent with aplastic anemia. In the English literature, aplastic anemia due to temozolomide is extremely rare.
  Case Reports in Medicine 01/2010; 2010:975039.
• Source

  Available from: Isin Soyuer

  Article: Cyclooxygenase-2 expression in gastrointestinal stromal tumours.

  Alper Sevinc, Celalettin Camci, Ibrahim Sari, Mehmet Emin Kalender, Ozlem Er, Isin Soyuer, Mustafa Dikilitas, Ugur Yilmaz, Ozgur Sagol, Ahmet Alacacioglu
  [show abstract] [hide abstract]
  ABSTRACT: While it is well known that cyclooxygenase-2 (COX-2) expression is increased in colorectal adenoma and carcinoma, there is only limited information on its status in stromal tumours. Immunohistochemical COX-2 staining was performed on a total of 42 confirmed gastrointestinal stromal tumours (GISTs) in the Pathology Department of Gaziantep University and the findings were compared with various other parameters. We found a statistically significant correlation between the tumor mitosis and COX-2 expression in GISTs. However, there was no relationship between COX-2 expression and death rate, presence of metastasis, tumour size, risk staging, usage of tyrosine kinase inhibitors, and complete resection rate. In the light of these findings, the usage of COX-2 inhibitors with or without tyrosine kinase inhibitors in GIST patients may be helpful in the adjuvant setting to prevent or delay recurrence. Moreover, we need more studies to define the status of COX-2 inhibitors in GISTs.
  Asian Pacific journal of cancer prevention: APJCP 01/2010; 11(4):849-53. · 0.66 Impact Factor
• Article: Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.

  Ramazan Yildiz, Mehmet Emin Kalender, Faysal Dane, Alper Sevinc, Mahmut Gumus, Celalettin Camci, Suleyman Alici, Ali Osman Kaya, Emel Yaman, Banu Ozturk, Ugur Coskun, Mustafa Benekli, Dogan Uncu, Suleyman Buyukberber
  [show abstract] [hide abstract]
  ABSTRACT: Platinum, antracyline, and fluoropyrimidine combination chemotherapy has been widely used as a first-line treatment for advanced gastric cancer (AGC). In the present study, we determined the efficacy and the safety of docetaxel and oral etoposide as second-line combination chemotherapy after failure of commonly used combination regimens in AGC. Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m(2) as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m(2) once daily on days 1-5, every 3 weeks until disease progression or unacceptable toxicities. Between June 2006 and September 2008, 32 patients, of median age 60 years (range 32-77 years) were included in the study. Overall response rate was 9.4% and 31.3% of patients achieved a stable disease. Median progression-free survival was 3 months (95% CI, 2.5-3.5). Median overall survival was 6 months (95% CI, 3.8-8.2) with 16.9% 1-year survival rate. Grade 3-4 toxicities included neutropenia (28.8%), febrile neutropenia (18.8%), thrombocytopenia (3.1%), nausea and vomiting (15.6%), diarrhea (9.4%), and mucositis (6.2%). Docetaxel and oral etoposide combination was moderately effective and safe in appropriately selected AGC patients after failure of platinum- and fluoropyrimidine-based combination regimens.
  Journal of Oncology Pharmacy Practice 10/2009; 16(3):173-8.
• Article: Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.

  Ugur Coskun, Necati Alkis, Gokhan Celenkoglu, Süleyman Buyukberber, Metin Ozkan, Celalettin Camci, Aytug Uner, Ozlem Er, Ulkü Yalcintas Aslan, Alper Sevinc, Saadet Tokluoglu, Banu Ozturk, Ramazan Yildiz, Mustafa Benekli
  [show abstract] [hide abstract]
  ABSTRACT: The aim of the study was to evaluate the efficacy and tolerability of gemcitabine and uracil-tegafur (UFT) combination in patients with advanced pancreatic carcinoma, retrospectively. Thirty-one patients, including 27 with metastatic disease, were treated with gemcitabine at a dose of 1000 mg/m2 in 30 minutes on days 1 and 8, and oral UFT 300 mg/m2 on days 1-14, as the first-line regimen in advanced stage. The cycle was repeated every 21 days. A total of 116 cycles of chemotherapy were administered, with a median of 3 cycles per patient (range 1-13). The objective response rate was observed in 6 (19.3%) patients with 1 (3.2%) complete response, and 5 (16.1%) partial responses. The median response duration was 4 (range, 3-14) months. Eight (25.8%) patients had a standard deviation of more than 3 months. Median overall survival was 8 months (95% CI, 6-10 months) and median time to progression was 4.2 months (95% CI, 1-6 months). This combination was generally well tolerated. There were no life-threatening side effects. Most common toxicities were of hematologic and gastrointestinal nature. In conclusion, this regimen was well tolerated and seemed to have a moderate activity in the palliative treatment of advanced pancreatic carcinoma.
  Journal of the National Medical Association 09/2009; 101(8):761-4. · 1.16 Impact Factor
• Article: A case of metachronous triple primary urogenital cancer: urinary bladder, prostate, and renal cancer.

  Cemile Arikan-Sengul, Yavuz Pehlivan, Alper Sevinc, Metin Karakok, Mehmet Emin Kalender, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: Multiple primary malignant tumors are rarely seen. Tobacco is one of the factors in their etiology. We report the case of a heavy smoker with metachronous triple primary cancer occurring in the prostate, kidney and urinary bladder. A 70-year-old man with prostate cancer presented with the complaint of hematuria. Computed tomography (CT) showed increased wall thickness of the urinary bladder with an enlarged prostate. After the trans-urothelial resection operation pathological diagnosis was consistent with transitional cell carcinoma of the urinary bladder. After 9 months of follow-up, the control CT showed metastatic lesions in the right and left kidneys and in the right lung. Bilateral partial nephrectomy was performed. Interestingly, renal cell carcinoma (RCC) was diagnosed. Rightsided video-assisted thoracoscopic surgery was also performed. The results of the histopathological examination were consistent with metastatic RCC. Although the patient presented with triple carcinoma, there was no familial cancer history suggesting a genetic association. The patient was a heavy smoker, and tobacco usage may be the underlying cause of the detected cancers. This is one of the rare cases in the published literature with triple primary urogenital cancer.
  Onkologie 04/2009; 32(3):122-4. · 0.87 Impact Factor
• Article: Detection of complete response to imatinib mesylate (Glivec((R))/Gleevec ((R))) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

  Mehmet Emin Kalender, Alper Sevinc, Mustafa Yilmaz, Coskun Ozsarac, Celalettin Camci
  Cancer Chemotherapy and Pharmacology 03/2009; 63(3):561. · 2.83 Impact Factor
• Article: The use of complementary therapies in cancer patients: a questionnaire-based descriptive survey from southeastern Turkey.

  Ozlem Ucan, Seda Pehlivan, Nimet Ovayolu, Alper Sevinc, Celalettin Camci
  [show abstract] [hide abstract]
  ABSTRACT: A study was designed to measure the frequency of complementary therapy (CT) usage in cancer patients in southeastern Turkey. The demographic characteristics associated with the use of CT are sought in patients undergoing or following conventional treatment. A descriptive survey was performed in a total of 560 cancer patients. Questionnaire-based measures of demographics, expectations, and effects of using different types of CT and perceived benefits were recorded. Demographic characteristics (age, gender, education status, etc.) did not differ among CT users and non-CT users. Three hundred ten patients (55.4%) had used at least one type of CT since the time of the initial diagnosis of cancer. The most frequently used CT method was herbal therapy, and the most commonly used herb was the stinging nettle. The source of information about CT was mainly from friends/family, whereas physicians and nurses played a small part in providing CT-related information. The majority of the patients used CT to benefit more from medical treatment. Only 20.7% of the patients considered themselves not benefiting from using CT. Currently more than half of Turkish patients with cancer use CT in addition to the standard medical approaches. CT usage is not associated with any specific demographic variables. Health professionals should not disregard the reality of CT usage in cancer patients. Because the majority of cancer patients use CT regardless of the medical advice, randomized clinical trials are needed to explore risks and benefits associated with CT modalities in cancer.
  American journal of clinical oncology 01/2009; 31(6):589-94. · 2.21 Impact Factor
• Article: Treatment of white coat hypertension with metformin.

  Mehmet Rami Helvaci, Alper Sevinc, Celalettin Camci, Atilla Yalcin
  [show abstract] [hide abstract]
  ABSTRACT: White coat hypertension (WCH) is most likely a disorder associated with metabolic syndrome. The study was performed at the Internal Medicine Polyclinic of Dumlupinar University on routine check-up patients. WCH cases who were overweight or obese and desiring weight loss were divided into two subgroups according to whether they preferred to achieve weight loss by medication or diet therapy. The study included 324 cases (204 females) with WCH, 45 of whom were in normal weight range. Therefore, 86.1% (279) of cases with WCH were either overweight or obese, and 41.3% (134) of all WCH cases had dyslipidemia. Twenty-five cases (14.7%) stopped metformin therapy due to excessive anorexia. At the end of a 6-month period, there were highly significant differences between the two groups with respect to the prevalences of resolved WCH, hyperbetalipoproteinemia, hypertriglyceridemia, dyslipidemia, overweight and obesity, and decreased fasting plasma glucose below 110 mg/dL (P < 0.001 for all). Due to gradually increased prevalences of impaired glucose tolerance, type 2 diabetes mellitus, dyslipidemia, excess body weight, and obesity-like disorders from sustained normotension towards WCH and hypertension (HT) cases, and very high prevalences of excess weight and dyslipidemia in the WCH group, WCH may be an associated disorder of metabolic syndrome rather than just being a predisposing factor of atherosclerosis or HT alone. Thus, the management of WCH should not focus solely on the regulation of blood pressure with antihypertensive medications, but rather on the prevention of future excess weight and various associated disorders, and metformin alone is an effective therapeutic option, most likely due to its powerful inhibitory effect on appetite.
  International Heart Journal 11/2008; 49(6):671-9. · 1.16 Impact Factor